2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.10 Impact of Pneumonitis from Radiotherapy Combined with Immune Checkpoint Inhibitor Therapy on Tumor Progression and Survival in Patients with Small Cell Lung Cancer

EP.13B.10 Impact of Pneumonitis from Radiotherapy Combined with Immune Checkpoint Inhibitor Therapy on Tumor Progression and Survival in Patients with Small Cell Lung Cancer

Back to course

Pdf Summary

The study presented by Ziwei Wang and colleagues from the Cancer Hospital Chinese Academy of Medical Sciences investigates the impact of pneumonitis on tumor progression and survival in patients with small cell lung cancer (SCLC) who undergo radiotherapy in combination with immune checkpoint inhibitor (ICI) therapy. The research focuses particularly on cases with extensive-stage (ES-SCLC) and limited-stage (LS-SCLC) small cell lung cancer.<br /><br />The introduction outlines how thoracic radiotherapy (TRT) combined with chemo-immunotherapy yields significant survival benefits in ES-SCLC patients. Despite these benefits, the combination increases rates of mild pneumonitis (grade 1–2), a potential concern due to its impact on progression and prognosis in SCLC patients.<br /><br />The methods utilized include a retrospective analysis of clinical and prognostic data, Kaplan-Meier survival analysis, and log-rank tests to study the correlation between treatment-induced pneumonitis, progression-free survival (PFS), and overall survival (OS). The study specifically examines ES-SCLC patients receiving consolidation TRT and LS-SCLC patients receiving concurrent or sequential TRT alongside ICI therapy. Pneumonitis was assessed and graded following the Common Terminology Criteria for Adverse Events (CTCAE 5.0).<br /><br />The results reveal that grade 2 pneumonitis associated with combined radiotherapy and immunotherapy shortens PFS for SCLC patients, although it does not affect OS. Mixed pneumonitis appears to have more adverse effects, suggesting a need for larger study samples for confirming these findings.<br /><br />Conclusions emphasize the necessity for careful risk assessment of pneumonitis when administering combined immunoradiotherapy for SCLC. This highlights the importance of weighing treatment benefits against potential adverse effects, providing a foundation for future studies aimed at optimizing treatment strategies for SCLC patients.

Asset Subtitle

Ziwei Wang

Meta Tag

Speaker Ziwei Wang

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

small cell lung cancer

pneumonitis

radiotherapy

immune checkpoint inhibitor

extensive-stage SCLC

limited-stage SCLC

progression-free survival

overall survival

thoracic radiotherapy

chemo-immunotherapy